Zenas BioPharma, Inc. (ZBIO)

Import this data to Google Sheets with:

=jivedata("ZBIO","financials")

Full statements spill as a table. For one cell: =jivedata("ZBIO","Revenue") or =jivedata("ZBIO","Revenue","TTM"). Install the Jive Data add-on, then paste into a cell.

Zenas BioPharma, Inc.

ZBIO • CIK 0001953926

(in thousands, except per share data)	FY 2024	FY 2025	TTM
Revenue from Contract with Customer, Excluding Assessed Tax	$5,000	$10,000	$1,000
Operating Income (Loss)	$-163,888	$-383,057	$-475,573
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest	$-156,559	$-377,816	$-484,164
Income Tax Expense (Benefit)	$429	$-79	$220
Net Income (Loss) Attributable to Parent	$-156,988	$-377,737	$-484,384
Weighted Average Number of Shares Outstanding, Basic	13,198,960	44,730,052	62,290,073
Research and Development Expense	$139,139	$168,063	$213,473
General and Administrative Expense	$29,749	$53,322	$61,428
Research and Development Asset Acquired Other than Through Business Combination, Fair Value Acquired	$10,000	$171,672	$171,672
Operating Expenses	$168,888	$393,057	$476,573
InterestExpenseNonoperating	—	$7,327	$7,327
Investment Income, Interest	—	$12,151	$15,636
Other Nonoperating Income (Expense)	$8,175	$417	$-6,103
Nonoperating Income (Expense)	$7,329	$5,241	$-8,591
OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax	$31	$156	$-1,007
Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent	$126	$-414	$-40
Comprehensive Income (Loss), Net of Tax, Attributable to Parent	$-156,831	$-377,995	$-485,431

(in thousands, except per share data)	FY 2024	FY 2025	TTM
Cash and Cash Equivalents, at Carrying Value	$319,742	$110,641	$196,577
Short-term Investments	$31,024	$232,551	$446,549
Property, Plant and Equipment, Net	$185	$34	$23
Restricted Cash, Current	$90	$90	$90
Operating Lease, Right-of-Use Asset	$1,004	$1,354	$821
Prepaid Expense and Other Assets, Current	$5,067	$7,979	$10,668
Long-term Investments	—	$17,272	$30,763
Assets, Current	$355,923	$351,171	$653,794
Other Assets, Noncurrent	$12,856	$13,809	$16,289
Assets	$369,968	$383,640	$701,690
Liabilities	$57,510	$141,496	$454,593
Accounts Payable, Current	$17,136	$7,111	$7,589
Accrued Liabilities, Current	$39,371	$54,423	$57,406
Operating Lease, Liability, Current	$785	$1,115	$823
Liabilities, Current	$57,292	$62,649	$65,818
Long-term Debt, Excluding Current Maturities	—	$78,636	$78,636
Operating Lease, Liability, Noncurrent	$218	$211	$22
Liabilities, Noncurrent	—	$78,847	$388,775
Common Stock, Value, Issued	$4	$5	$6
Additional Paid in Capital	$699,651	$1,007,331	$1,205,803
Accumulated Other Comprehensive Income (Loss), Net of Tax	$194	$-64	$-1,141
Retained Earnings (Accumulated Deficit)	$-387,391	$-765,128	$-957,571
Stockholders' Equity Attributable to Parent	$312,458	$242,144	$247,097
Preferred Stock, Shares Authorized	25,000,000	25,000,000	25,000,000
Preferred Stock, Shares Issued	0	0	0
Common Stock, Shares Authorized	175,000,000	175,000,000	175,000,000
Common Stock, Shares, Issued	41,793,412	54,485,518	63,330,747

(in thousands, except per share data)	FY 2024	FY 2025	TTM
Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations	$157	$-252	$-1,038
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect	$262,889	$-209,191	$152,571
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents	$319,832	$110,641	$414,311
Net Income (Loss) Attributable to Parent	$-156,988	$-377,737	$-484,384
Research and Development Asset Acquired Other than Through Business Combination, Fair Value Acquired	$10,000	$171,672	$171,672
Depreciation	$137	$56	$31
Gain (Loss) on Disposition of Property Plant Equipment	—	$-107	$-107
Amortization of Debt Discount (Premium)	$-602	$-1,931	$-2,011
Share-based Payment Arrangement, Noncash Expense	$10,821	$26,347	$32,730
Increase (Decrease) in Prepaid Expense and Other Assets	$7,701	$3,156	$9,331
Increase (Decrease) in Accounts Payable	$11,740	$-10,043	$-377
Increase (Decrease) in Accrued Liabilities	$22,065	$15,052	$12,878
IncreaseDecreaseInOperatingLeaseLiability	$-673	$-902	$-937
Net Cash Provided by (Used in) Operating Activities	$-119,674	$-172,333	$-225,972
Payments to Acquire Property, Plant, and Equipment	$131	$18	$2
Payments to Acquire Investments	$36,421	$417,755	$600,418
Proceeds from Sale, Maturity and Collection of Investments	$6,000	$200,887	$356,006
Net Cash Provided by (Used in) Investing Activities	$-30,552	$-251,886	$-309,414
Proceeds from Issuance of Redeemable Convertible Preferred Stock	$178,381	$178,381	$178,381
Payments of Stock Issuance Costs	$6,334	—	—
Proceeds from Issuance of Debt	—	$75,000	$75,000
Proceeds from Stock Options Exercised	$275	$4,096	$3,448
Proceeds from Stock Plans	—	$276	$276
Proceeds from Issuance Initial Public Offering	$240,636	—	$240,636
Net Cash Provided by (Used in) Financing Activities	$412,958	$215,280	$688,995
Right-of-Use Asset Obtained in Exchange for Operating Lease Liability	$1,100	$1,500	$1,500
Conversion of Stock, Amount Converted	$449,612	$449,612	$449,612
Notes Assumed	$21,146	$21,146	$21,146
Cash and Cash Equivalents, at Carrying Value	$319,742	$110,641	$414,311
Restricted Cash, Current	$90	$90	$90

Loading financial statements…

Import this data to Google Sheets with:

=jivedata("ZBIO","financials")

Full statements spill as a table. For one cell: =jivedata("ZBIO","Revenue") or =jivedata("ZBIO","Revenue","TTM"). Install the Jive Data add-on, then paste into a cell.